Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025)

Protalix BioTherapeutics has reported Retained Earnings for 16 years, with the latest figure at -$385.0 million in Q4 2025.

• On a quarterly basis, Retained Earnings fell 1.75% year-over-year to -$385.0 million in Q4 2025; TTM through Dec 2025 was -$385.0 million, a 1.75% decrease from a year earlier, with the FY2025 full-year figure at -$385.0 million, down 1.75% from the prior year.
• Retained Earnings was -$385.0 million for Q4 2025 at Protalix BioTherapeutics, down from -$378.4 million in the prior quarter.
• The five-year high for Retained Earnings was -$374.9 million in Q4 2021, with the low at -$389.9 million in Q4 2022.
• Average Retained Earnings over 5 years is -$381.9 million, with a median of -$381.5 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Retained Earnings declined 7.94% in 2021, then rose 2.13% in 2023.
• Over 5 years, Retained Earnings stood at -$374.9 million in 2021, then slipped by 3.98% to -$389.9 million in 2022, then climbed by 2.13% to -$381.5 million in 2023, then climbed by 0.83% to -$378.4 million in 2024, then dropped by 1.75% to -$385.0 million in 2025.
• The last three Retained Earnings figures came in at -$385.0 million (Q4 2025), -$378.4 million (Q4 2024), and -$381.5 million (Q4 2023), per Business Quant data.